Syneos Health® has completed the previously announced acquisition of Synteract, a CRO focused on the biopharma segment.
“With Synteract, we are answering the strong demand we are seeing in the small- to mid-sized space, fueled by near all-time high funding. The specialized Synteract team will maintain their laser-focus on partnering with emerging biopharma companies, while benefiting from the scale and horsepower of Syneos Health. We welcome Synteract employees and customers to the Syneos Health family and look forward to collectively expanding our impact for patients,” Alistair Macdonald, Chief Executive Officer, Syneos Health, said,
Synteract will maintain its brand, operating as a Syneos Health Business Unit and will be led by Synteract President, Steve Powell.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!